Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BEYAZ vs ADQUEY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and drospirenone suppresses gonadotropins (FSH and LH) from the pituitary, inhibiting ovulation, altering cervical mucus, and inducing endometrial changes. Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity.
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
Contraception,Treatment of premenstrual dysphoric disorder (PMDD),Treatment of moderate acne vulgaris in women at least 14 years old who have achieved menarche and desire contraception
Alzheimer disease (FDA approved for treatment of mild cognitive impairment or mild dementia stage),Off-label: none established
One tablet (drospirenone 3 mg / ethinyl estradiol 0.02 mg) orally once daily for 24 days, followed by 4 days of placebo.
400 mg orally once daily with food.
Drospirenone: approximately 30 hours (terminal). Ethinyl estradiol: approximately 13-15 hours (terminal). Steady-state reached within 10 days. Clinical context: once-daily dosing maintains therapeutic levels with minimal accumulation after 3-4 cycles.
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min)
Primarily hepatic via CYP3A4. Ethinyl estradiol undergoes first-pass metabolism in the liver and gut wall. Drospirenone is metabolized via CYP3A4 and also undergoes reduction and sulfation. Metabolites are excreted in urine and feces.
Metabolized via catabolic pathways similar to endogenous Ig G; no specific cytochrome P450 enzyme involvement.
Urine (45-55% as metabolites), feces (30-40% as metabolites), with enterohepatic recirculation of ethinyl estradiol metabolites.
Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%)
Drospirenone: 95-97% bound (primarily to albumin). Ethinyl estradiol: approximately 98% bound (mostly to albumin).
98% bound to albumin
Drospirenone: approximately 3.7 L/kg (suggests moderate tissue distribution). Ethinyl estradiol: approximately 3.6 L/kg (consistent with distribution into body water). Clinical meaning: not extensively stored in tissues.
0.2-0.3 L/kg; indicates limited extravascular distribution
Oral: Drospirenone ~76% (relative to IV). Ethinyl estradiol ~55% (due to first-pass metabolism).
Oral: 85-90%; IM: 95-100%
Contraindicated in patients with renal impairment (creatinine clearance < 50 m L/min). No dose adjustment is recommended for mild impairment (Cr Cl >= 50 m L/min); however, careful monitoring is advised.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: 200 mg daily; Cr Cl <30 m L/min: 100 mg daily; hemodialysis: 100 mg daily after dialysis.
Contraindicated in patients with hepatic impairment (Child-Pugh class A, B, or C). Do not use in acute or chronic liver disease.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg daily; Child-Pugh C: not recommended.
Not indicated for use before menarche. For postmenarchal adolescents, dose is same as adults: one tablet daily following the 24/4 regimen.
Weight ≥10 kg: 12 mg/kg/dose twice daily; weight <10 kg: 8 mg/kg/dose twice daily.
Not indicated for use in postmenopausal women. No specific geriatric dosing is established; use not recommended in this population.
Initial dose 200 mg daily; titrate based on renal function; monitor for neuropsychiatric effects.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COCs). This risk increases with age, especially in women over 35 years, and with the number of cigarettes smoked. Women who use COCs should be strongly advised not to smoke.
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), can occur. ARIA is usually asymptomatic but serious events including seizure and status epilepticus have been reported. Patients with apolipoprotein E ε4 homozygosity have a higher incidence of ARIA.
Thrombotic disorders: venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction,Hepatic disease: jaundice, cholestasis, hepatic adenomas,Hypertension: monitor blood pressure,Hyperkalemia: risk in patients with renal impairment, hepatic impairment, or adrenal insufficiency; avoid use with potassium-sparing diuretics or potassium supplements,Gallbladder disease,Carbohydrate and lipid metabolic effects,Headache/migraine,Bleeding irregularities,Depression,Carcinoma: breast and cervical,Ocular lesions: retinal thrombosis
1) Amyloid-related imaging abnormalities (ARIA): monitor with MRI before and during treatment; consider dose interruption or discontinuation if severe. 2) Hypersensitivity reactions: angioedema, urticaria reported. 3) Risk of falls due to cognitive impairment. 4) No head-to-head trials showing superiority over other treatments.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer,Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenomas or carcinomas (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Renal impairment,Adrenal insufficiency,Hyperkalemia,Use with potassium-sparing diuretics, potassium supplements, or other drugs that increase potassium
History of severe hypersensitivity to aducanumab or any excipients in ADQUEY.
Grapefruit and grapefruit juice should be avoided as they inhibit CYP3A4, potentially increasing ethinyl estradiol levels and risk of adverse effects. No other specific food interactions are documented, but consider that high potassium foods (e.g., bananas, oranges, spinach) may theoretically contribute to hyperkalemia in susceptible patients, though routine avoidance is not required. Alcohol may increase the risk of liver toxicity, but moderate use is not contraindicated.
Avoid grapefruit and grapefruit juice; may increase drug levels. High-fat meals can increase absorption; take with food or on an empty stomach consistently.
Pregnancy category X. Contraindicated in pregnancy due to known teratogenic effects, including cardiovascular and skeletal anomalies, particularly during first trimester. Use during second and third trimesters is associated with feminization of male fetuses and potential hepatic adenoma. Discontinue immediately if pregnancy occurs.
ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may lead to feminization of male fetuses and other adverse outcomes.
Excreted in human breast milk. M/P ratio not determined. Can reduce milk production and composition. Use is generally contraindicated during breastfeeding due to potential adverse effects in the infant, including jaundice and fluid retention.
Excretion into breast milk is minimal; however, ADQUEY may reduce milk production and quality. M/P ratio not established. Avoid use during breastfeeding.
Not applicable: contraindicated during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased clearance) are irrelevant as drug should be discontinued.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately if pregnancy occurs.
BEYAZ (drospirenone/ethinyl estradiol) is a combined oral contraceptive (COC) with a 24/4 regimen. The drospirenone component has antimineralocorticoid activity, which can be beneficial for patients with fluid retention or acne. Monitor potassium levels in patients on concomitant medications that increase potassium (e.g., ACE inhibitors, ARBs, NSAIDs). BEYAZ is contraindicated in patients with renal impairment (Cr Cl <30 m L/min) due to risk of hyperkalemia. The 24 active pill regimen provides a longer window of ovulation suppression and may reduce breakthrough bleeding compared to 21-day regimens. Use with caution in patients with a history of depression; drospirenone may affect mood.
Administration with a full glass of water and staying upright for 30 minutes reduces risk of esophagitis. Monitor for cutaneous lupus erythematosus and Stevens-Johnson syndrome. Avoid concomitant use with drugs that prolong QT interval due to risk of torsades de pointes.
Take one pill at the same time each day, preferably in the evening to minimize nausea.,If you miss a pill, follow the package insert instructions: for one missed pill, take it as soon as remembered; for two or more missed pills, use backup contraception (e.g., condoms) for at least 7 days.,Avoid eating grapefruit or drinking grapefruit juice while taking this medication because it can increase estrogen levels and risk of side effects.,Do not smoke while using BEYAZ, especially if you are over 35, as smoking increases the risk of serious cardiovascular events.,Side effects may include nausea, breast tenderness, headache, and mood changes; report persistent symptoms to your provider.,Seek immediate medical attention if you experience signs of a blood clot: sudden leg swelling, chest pain, shortness of breath, or sudden severe headache.,BEYAZ does not protect against HIV or other sexually transmitted infections; use condoms for protection.
Take exactly as prescribed; do not double doses if missed.,Swallow tablet whole; do not crush or chew.,Avoid direct sunlight; use sunscreen and protective clothing.,Report any skin rash, blisters, or eye irritation immediately.,Do not take with antacids, iron supplements, or sucralfate; separate by at least 4 hours.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BEYAZ vs ADQUEY, answered by our medical review team.
BEYAZ is a Oral Contraceptive that works by Combination of ethinyl estradiol and drospirenone suppresses gonadotropins (FSH and LH) from the pituitary, inhibiting ovulation, altering cervical mucus, and inducing endometrial changes. Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity.. ADQUEY is a Oral Contraceptive that works by ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BEYAZ and ADQUEY depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BEYAZ is: One tablet (drospirenone 3 mg / ethinyl estradiol 0.02 mg) orally once daily for 24 days, followed by 4 days of placebo.. The standard adult dose of ADQUEY is: 400 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BEYAZ and ADQUEY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BEYAZ is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to known teratogenic effects, including cardiovascular and skeletal anomalies, particularly during first trimester. Use durin. ADQUEY is classified as Category C. ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Sec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.